Beijing Tiantan Biological Products Co., Ltd. (SHA:600161)
China · Delayed Price · Currency is CNY 12.83
0.00 (0.00%)
Jul 31, 2026, 3:00 PM CST
SHA:600161 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 25,370 | 32,310 | 40,536 | 50,983 | 39,103 | 39,767 | |
Market Cap Growth | -36.92% | -20.29% | -20.49% | 30.38% | -1.67% | -23.98% |
Enterprise Value | 27,204 | 34,128 | 38,978 | 49,023 | 37,846 | 37,744 |
Last Close Price | 12.83 | 16.27 | 20.15 | 25.22 | 19.30 | 19.55 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 26.37 | 29.62 | 26.17 | 45.94 | 44.39 | 52.33 |
Forward PE | 35.06 | 19.57 | 29.48 | 39.63 | 39.14 | 45.04 |
PS Ratio | 4.23 | 5.24 | 6.72 | 9.84 | 9.18 | 9.67 |
PB Ratio | 1.64 | 2.11 | 2.79 | 4.00 | 3.44 | 3.87 |
P/TBV Ratio | 2.43 | 3.14 | 4.20 | 5.69 | 4.78 | 5.27 |
P/FCF Ratio | - | - | - | 38.74 | - | - |
P/OCF Ratio | 40.60 | 95.38 | 49.45 | 21.30 | 34.73 | 40.56 |
PEG Ratio | - | 3.91 | 1.88 | 2.21 | 2.21 | 2.21 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.54 | 5.53 | 6.46 | 9.46 | 8.88 | 9.18 |
EV/EBITDA Ratio | 13.35 | 15.66 | 13.90 | 25.08 | 26.07 | 28.75 |
EV/EBIT Ratio | 16.96 | 19.16 | 15.77 | 28.73 | 29.27 | 32.15 |
EV/FCF Ratio | - | - | - | 37.25 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | 0.00 | 0.04 | 0.05 |
Debt / EBITDA Ratio | 0.05 | 0.07 | 0.02 | 0.02 | 0.27 | 0.38 |
Debt / FCF Ratio | - | - | - | 0.03 | - | - |
Net Debt / Equity Ratio | -0.12 | -0.12 | -0.18 | -0.35 | -0.29 | -0.37 |
Net Debt / EBITDA Ratio | -0.89 | -0.84 | -0.94 | -2.31 | -2.28 | -2.91 |
Net Debt / FCF Ratio | 76.93 | 6.86 | 10.63 | -3.43 | 14.52 | 25.25 |
Asset Turnover | 0.36 | 0.38 | 0.40 | 0.38 | 0.35 | 0.43 |
Inventory Turnover | 0.87 | 0.89 | 0.82 | 0.99 | 0.97 | 1.00 |
Quick Ratio | 4.40 | 4.06 | 3.41 | 3.66 | 4.25 | 6.65 |
Current Ratio | 8.82 | 8.00 | 6.89 | 5.92 | 6.28 | 9.32 |
Return on Equity (ROE) | 8.77% | 9.98% | 15.48% | 12.52% | 11.14% | 13.12% |
Return on Assets (ROA) | 6.09% | 6.86% | 10.28% | 7.87% | 6.59% | 7.68% |
Return on Invested Capital (ROIC) | 9.58% | 11.47% | 20.35% | 17.58% | 15.07% | 17.54% |
Return on Capital Employed (ROCE) | 10.20% | 11.50% | 16.80% | 13.20% | 11.00% | 10.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.83% | 3.38% | 3.82% | 2.18% | 2.25% | 1.91% |
FCF Yield | -0.09% | -0.83% | -0.61% | 2.58% | -0.58% | -0.38% |
Dividend Yield | 1.56% | 1.23% | 0.50% | 0.50% | 0.22% | 0.36% |
Payout Ratio | 50.83% | 45.32% | 15.96% | 8.47% | 17.85% | 21.56% |
Buyback Yield / Dilution | 0.04% | 0.14% | -0.21% | 0.62% | -2.79% | -7.41% |
Total Shareholder Return | 1.60% | 1.37% | 0.29% | 1.12% | -2.57% | -7.06% |